Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | ACVR2A | P27037 | 7/20 | 0.37 |
| ▸ | TGFBR2 | P37173 | 7/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16114689 | 0.84 | CNR1 (0.42) | CNR1DYRK1AACVR2ATGFBR2GRM2 | |
| SCHEMBL17633299 | 0.82 | AAK1 (0.46) | CNR1DYRK1AACVR2ATGFBR2CYP3A4 | |
| SCHEMBL30995101 | 0.74 | CNR1 (0.47) | CNR1DYRK1AACVR2ATGFBR2IDO1 | |
| SCHEMBL23674568 | 0.72 | CNR1 (0.44) | CNR1DYRK1AACVR2ATGFBR2GRM2 | |
| SCHEMBL30042422 | 0.72 | CNR1 (0.44) | CNR1DYRK1AACVR2ATGFBR2GRM2 | |
| SCHEMBL28203431 | 0.71 | CNR1 (0.44) | CNR1DYRK1AACVR2ATGFBR2IDO1 | |
| SCHEMBL19620153 | 0.70 | MAP4K4 (0.43) | PDE3BPDE3A | |
| SCHEMBL30078861 | 0.67 | — | — | |
| SCHEMBL676002 | 0.67 | — | — | |
| SCHEMBL30626327 | 0.67 | LOX (0.55) | CNR1DYRK1AACVR2ATGFBR2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-9822102-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | OGFOD1, VASP, PNPO | CNR1 1212/4885DYRK1A 2791/4885ACVR2A 2556/4885 |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | OGFOD1, PNPO, VASP | CNR1 1092/4885DYRK1A 2096/4885ACVR2A 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.